Treatment of Clostridium difficile Infection
For initial episodes of C. difficile infection (CDI), either vancomycin 125 mg orally four times daily or fidaxomicin 200 mg orally twice daily for 10 days is recommended over metronidazole as first-line therapy. 1, 2
Treatment Algorithm Based on Disease Severity
Initial Episode Classification and Treatment
Non-severe CDI (Adults)
Severe CDI (Adults)
Fulminant CDI (Adults)
- Definition: Hypotension, shock, ileus, or megacolon 1
- Treatment:
Pediatric Treatment (6 months to <18 years)
Non-severe CDI
- Treatment:
Severe/Fulminant CDI
- Treatment:
Management of Recurrent CDI
First Recurrence
If metronidazole was used for initial episode:
If standard vancomycin was used for initial episode:
Second or Subsequent Recurrence
- Options include:
Monitoring Treatment Response
- Expect decreased stool frequency and improved consistency within 3 days of starting treatment 2
- If no improvement after 3-5 days, reassess severity and consider alternative diagnoses 2
Important Considerations and Pitfalls
Avoid metronidazole for severe CDI: Despite its lower cost, metronidazole is less effective than vancomycin for severe cases and should be reserved only for non-severe cases when access to vancomycin/fidaxomicin is limited 1
Discontinue inciting antibiotics: Failure to stop the triggering antibiotic significantly increases recurrence risk 1, 2
Avoid antiperistaltic agents: These can mask symptoms and potentially worsen disease 2
Dosing controversy: While some studies have examined higher doses of vancomycin for severe CDI, current evidence does not support routine use of doses higher than those recommended in guidelines 6, 7, 8
Recurrence prevention: Fidaxomicin has shown superiority in preventing recurrence compared to vancomycin (19.7% vs 35.5% recurrence rates) 5
Surgical consultation: Early surgical evaluation is recommended for patients with perforation, systemic inflammation not responding to antibiotics, toxic megacolon, severe ileus, or serum lactate >5.0 mmol/L 2
Vancomycin absorption: While oral vancomycin is minimally absorbed, patients with inflammatory bowel disorders may have significant systemic absorption, requiring monitoring in those with renal insufficiency 3